ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis - GlobeNewswire

ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided Endocarditis  GlobeNewswire

Comments

Popular posts from this blog

What is Noma (Cancrum oris)? - News-Medical.Net

Urinary Tract Infection (UTI): Causes, Symptoms & Treatment - Cleveland Clinic